GEA has taken the lead in providing the pharmaceutical industry with new technologies based on the most innovative way of granulating, drying and making tablets using potent APIs. The company has pioneered continuous manufacturing in drug production and was the first supplier to provide and install a complete powder-to-tablet line for customer use.
The pharmaceutical industry is looking at continuous processing to improve production quality in an efficient and cost-effective way and to comply with the increasingly stringent manufacturing acceptance criteria put in place by the regulatory authorities.
The ConsiGma™ continuous high shear granulation and drying system is a multipurpose platform that has been designed to transfer powder into coated tablets in development, pilot, clinical and production volumes in a single compact unit. The system can perform dosing and mixing of raw materials, wet or dry granulation, drying, tableting and quality control, all in one line. By producing granules continuously, batch sizes are determined by how long you run the machine; and, because of ConsiGma™’s innovative design, the amount of waste produced during start-up and shut down is significantly reduced compared with conventional methods. Quality is measured throughout the process and, as such, drastically reduces the cost per tablet.
Typical applications for ConsiGma™ include producing small batches of high added value products, the production/launch of new molecules, reformulations and current non-robust processes, formulations with specific granulation and/or drying issues, site changes or increases in production and more economic and greener production methods. ConsiGma™ offers
ConsiGma™ was developed in compliance with the FDA’s QbD initiative. It satisfies the industry’s need for reduced risk and higher quality while avoiding lengthy and costly validation and scale-up to bring products to market faster and cheaper. The inherent flexibility enables manufacturers to meet demand, keep expensive cleanroom space to a minimum and reduce inventory costs.
Optionally integrated advanced process control and PAT tools enable monitoring during production, so quality can be designed into products from the start. ConsiGma™ provides maximum output in an energy efficient way, has been tested using more than 100 different formulations and is already being used by several large pharmaceutical companies, and ethical and generic research and manufacturing centres worldwide.
Avoid upfront investment and preserve capital. GEA Financial Services offer to you attractive conditions to lease your new GEA equipment. Cost occur over time while the machine is used.
Video support designed to provide remote assistance in real-time.
The project team at a major pharmaceutical manufacturing company initiated an in-depth feasibility study to assess the capabilities and constraints of ConsiGma®’s technology and process characteristics.Read more
Stay in touch with GEA innovations and stories by signing up for news from GEA.Sign up
We are here to help! With just a few details we will be able to respond to your inquiry.Contact us